UNIVERSITY OF ILLINOIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.illinois.edu

Clinical Trials

Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.

Completed

Conditions: Raynaud's Disease

First Posted Date: 2015-11-26

Last Posted Date: 2016-05-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 5

Registration Number: NCT02615964

Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease

Not Applicable

Completed

Conditions: Sickle Cell Disease
Stress

Interventions: Behavioral: Guided audio-visual relaxation

First Posted Date: 2015-07-17

Last Posted Date: 2015-07-17

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 28

Registration Number: NCT02501447

Asthma Action at Erie Trial

Phase 3

Completed

Conditions: Asthma
Children

Interventions: Behavioral: Community Health Worker
Behavioral: Certified asthma educator

First Posted Date: 2015-06-25

Last Posted Date: 2021-12-09

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 223

Registration Number: NCT02481986

Locations: 🇺🇸
Erie Family Health Center, Chicago, Illinois, United States

Cannabinoid Control of Fear Extinction Neural Circuits in Humans

Phase 4

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2015-06-16

Last Posted Date: 2015-08-25

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 85

Registration Number: NCT02472847

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Lab Work
Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
Drug: Certolizumab pegol (CDP870, tradename Cimzia)
Drug: Hydroxychloroquine
Drug: Sulfasalazine
Drug: Medrol
Drug: Prednisone
Drug: Triamcinolone
Drug: Naproxen
Drug: Leflunomide
Drug: Methotrexate
Drug: humira

First Posted Date: 2015-05-22

Last Posted Date: 2024-07-10

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 32

Registration Number: NCT02451748

Locations: 🇺🇸
Outpatient Care Center, Chicago, Illinois, United States

A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: tacrolimus extended release

First Posted Date: 2015-05-14

Last Posted Date: 2018-11-07

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 20

Registration Number: NCT02444143

Locations: 🇺🇸
University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Omacetaxine mepesuccinate

First Posted Date: 2015-05-12

Last Posted Date: 2021-07-06

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 22

Registration Number: NCT02440568

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management

Not Applicable

Completed

Conditions: Pediatric Obesity

Interventions: Behavioral: Exergaming
Behavioral: Didactic health teaching

First Posted Date: 2015-05-06

Last Posted Date: 2015-12-14

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 84

Registration Number: NCT02436330

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

Not Applicable

Completed

Conditions: Kidney Transplant

Interventions: Behavioral: Exercise Rehabilitation

First Posted Date: 2015-04-07

Last Posted Date: 2024-11-11

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 135

Registration Number: NCT02409901

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Phase 4

Recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Flecainide
Drug: Sotalol

First Posted Date: 2015-01-27

Last Posted Date: 2024-08-01

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 162

Registration Number: NCT02347111

Locations: 🇺🇸
Jesse Brown VA Medical Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy